Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin Rollover Study
NCT04299880Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Feb 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of napabucasin in solid tumor (5 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Feb 2020; status: completed.
02
Drugs
napabucasin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04299880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04299880.